Lipophilic Antifolate Trimetrexate is a Potent Inhibitor of Trypanosoma Cruzi: Prospect for Chemotherapy of Chagas' Disease

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2005 Jul 29

PMID 16048931

Citations 9

Authors

Olga Senkovich

Vandanajay Bhatia

Nisha Garg

Debasish Chattopadhyay

Affiliations

Soon will be listed here.

Abstract

Trypanosoma cruzi, a protozoan parasite, is the causative agent for Chagas' disease, which poses serious public health problem in Latin America. The two drugs available for the treatment of this disease are effective only against recent infections and are toxic. Dihydrofolate reductase (DHFR) has a proven track record as a drug target. The lipophilic antifolate trimetrexate (TMQ), which is an FDA-approved drug for the treatment of Pneumocystis carinii infection in AIDS patients, is a potent inhibitor of T. cruzi DHFR activity, with an inhibitory constant of 6.6 nM. The compound is also highly effective in killing T. cruzi parasites. The 50 and 90% lethal dose values against the trypomastigote are 19 and 36 nM, and the corresponding values for the amastigote form are 26 and 72 nM, respectively. However, as TMQ is also a good inhibitor of human DHFR, further improvement of the selectivity of this drug would be preferable. Identification of a novel antifolate selective against T. cruzi would open up new therapeutic avenues for treatment of Chagas' disease.

Citing Articles

Targeting one-carbon metabolism for cancer immunotherapy.

Ren X, Wang X, Zheng G, Wang S, Wang Q, Yuan M Clin Transl Med. 2024; 14(1):e1521.

PMID: 38279895 PMC: 10819114. DOI: 10.1002/ctm2.1521.

Optimization of the 2-arylquinazoline-4(3)one scaffold for a selective and potent antitrypanosomal agent: modulation of the mechanism of action through chemical functionalization.

Romero A, Aguilera E, Gotopo L, Cabrera G, Davila B, Cerecetto H RSC Med Chem. 2023; 14(10):1992-2006.

PMID: 37859724 PMC: 10583831. DOI: 10.1039/d3md00243h.

Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers.

Sun W, Liu R, Gao X, Lin Z, Tang H, Cui H Biomark Res. 2023; 11(1):48.

PMID: 37147729 PMC: 10161514. DOI: 10.1186/s40364-023-00487-4.

The TcrNT2 Nucleoside Transporter Is a Conduit for the Uptake of 5-F-2'-Deoxyuridine and Tubercidin Analogues.

Aldfer M, Alfayez I, Elati H, Gayen N, Elmahallawy E, Murillo A Molecules. 2022; 27(22).

PMID: 36432150 PMC: 9693223. DOI: 10.3390/molecules27228045.

A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight.

Cuthbertson C, Arabzada Z, Bankhead 3rd A, Kyani A, Neamati N ACS Pharmacol Transl Sci. 2021; 4(2):624-646.

PMID: 33860190 PMC: 8033767. DOI: 10.1021/acsptsci.0c00223.

References

Zuccotto F, Zvelebil M, Brun R, Chowdhury S, Di Lucrezia R, Leal I . Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase. Eur J Med Chem. 2001; 36(5):395-405. DOI: 10.1016/s0223-5234(01)01235-1. View

Zuccotto F, Brun R, Gonzalez Pacanowska D, Ruiz Perez L, GILBERT I . The structure-based design and synthesis of selective inhibitors of Trypanosoma cruzi dihydrofolate reductase. Bioorg Med Chem Lett. 1999; 9(10):1463-8. DOI: 10.1016/s0960-894x(99)00213-9. View

Whitlow M, Howard A, Stewart D, HARDMAN K, Chan J, Baccanari D . X-Ray crystal structures of Candida albicans dihydrofolate reductase: high resolution ternary complexes in which the dihydronicotinamide moiety of NADPH is displaced by an inhibitor. J Med Chem. 2001; 44(18):2928-32. DOI: 10.1021/jm0101444. View

Rodriques Coura J, de Castro S . A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2002; 97(1):3-24. DOI: 10.1590/s0074-02762002000100001. View

Gilbert I . Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes. Biochim Biophys Acta. 2002; 1587(2-3):249-57. DOI: 10.1016/s0925-4439(02)00088-1. View

Klon A, Heroux A, Ross L, Pathak V, Johnson C, Piper J . Atomic structures of human dihydrofolate reductase complexed with NADPH and two lipophilic antifolates at 1.09 a and 1.05 a resolution. J Mol Biol. 2002; 320(3):677-93. DOI: 10.1016/s0022-2836(02)00469-2. View

Urbina J, Payares G, Sanoja C, Molina J, Lira R, Brener Z . Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agents. 2003; 21(1):39-48. DOI: 10.1016/s0924-8579(02)00274-1. View

Senkovich O, Pal B, Schormann N, Chattopadhyay D . Trypanosoma cruzi genome encodes a pteridine reductase 2 protein. Mol Biochem Parasitol. 2003; 127(1):89-92. DOI: 10.1016/s0166-6851(02)00309-2. View

McGuire J . Anticancer antifolates: current status and future directions. Curr Pharm Des. 2003; 9(31):2593-613. DOI: 10.2174/1381612033453712. View

10.

Ren H, Grady S, Banghart M, Moulthrop J, Kendrick H, Yardley V . Synthesis and in vitro anti-protozoal activity of a series of benzotropolone derivatives incorporating endocyclic hydrazines. Eur J Med Chem. 2003; 38(11-12):949-57. DOI: 10.1016/j.ejmech.2003.07.004. View

11.

Grossman P, Remington J . The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo. Am J Trop Med Hyg. 1979; 28(3):445-55. DOI: 10.4269/ajtmh.1979.28.445. View

12.

Winston D, Lau W, Gale R, Young L . Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med. 1980; 92(6):762-9. DOI: 10.7326/0003-4819-92-6-762. View

13.

FERONE R, Roland S . Dihydrofolate reductase: thymidylate synthase, a bifunctional polypeptide from Crithidia fasciculata. Proc Natl Acad Sci U S A. 1980; 77(10):5802-6. PMC: 350159. DOI: 10.1073/pnas.77.10.5802. View

14.

Allegra C, Kovacs J, Drake J, Swan J, Chabner B, Masur H . Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest. 1987; 79(2):478-82. PMC: 424107. DOI: 10.1172/JCI112837. View

15.

Allegra C, Kovacs J, Drake J, Swan J, Chabner B, Masur H . Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med. 1987; 165(3):926-31. PMC: 2188293. DOI: 10.1084/jem.165.3.926. View

16.

Scott D, Coombs G, Sanderson B . Folate utilisation by Leishmania species and the identification of intracellular derivatives and folate-metabolising enzymes. Mol Biochem Parasitol. 1987; 23(2):139-49. DOI: 10.1016/0166-6851(87)90149-6. View

17.

Kovacs J, Allegra C, Swan J, Drake J, Parrillo J, Chabner B . Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob Agents Chemother. 1988; 32(4):430-3. PMC: 172195. DOI: 10.1128/AAC.32.4.430. View

18.

Sirawaraporn W, Sertsrivanich R, Booth R, HANSCH C, Neal R, Santi D . Selective inhibition of Leishmania dihydrofolate reductase and Leishmania growth by 5-benzyl-2,4-diaminopyrimidines. Mol Biochem Parasitol. 1988; 31(1):79-85. DOI: 10.1016/0166-6851(88)90147-8. View

19.

Berman J, King M, Edwards N . Antileishmanial activities of 2,4-diaminoquinazoline putative dihydrofolate reductase inhibitors. Antimicrob Agents Chemother. 1989; 33(11):1860-3. PMC: 172777. DOI: 10.1128/AAC.33.11.1860. View

20.

Nare B, Luba J, Hardy L, Beverley S . New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity. Parasitology. 1997; 114 Suppl:S101-10. View